BriaCell closes $8.5M public offering of 12.3M shares at $0.69 each

BriaCell Therapeutics Corp.

Gross proceeds of $8,504,250 from sale of 12,325,000 common shares at $0.69/share.
Placement agent ThinkEquity received 7.5% cash fee and 5-year warrants for 616,250 shares at $0.8625.
Net proceeds to be used for working capital, general corporate purposes, and advancing business objectives.
Offering closed on September 12, 2024; securities sold under effective shelf registration statement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.